Trial · NCT00770653
Adverse events58
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 58
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Pioglitazone 15 mg and Metformin 850 mg BID | 8 | 153 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Glimepiride 2 mg and Metformin 850 mg BID | 3 | 149 | |
| other | Diarrhoea | Gastrointestinal disorders | Pioglitazone 15 mg and Metformin 850 mg BID | 14 | 153 | |
| other | Diarrhoea | Gastrointestinal disorders | Glimepiride 2 mg and Metformin 850 mg BID | 14 | 149 | |
| other | Headache | Nervous system disorders | Pioglitazone 15 mg and Metformin 850 mg BID | 7 | 153 | |
| other | Headache | Nervous system disorders | Glimepiride 2 mg and Metformin 850 mg BID | 7 | 149 | |
| other | Nasopharyngitis | Infections and infestations | Pioglitazone 15 mg and Metformin 850 mg BID | 24 | 153 | |
| other | Nasopharyngitis | Infections and infestations | Glimepiride 2 mg and Metformin 850 mg BID | 33 | 149 | |
| other | Oedema peripheral | General disorders | Pioglitazone 15 mg and Metformin 850 mg BID | 8 | 153 | |
| other | Oedema peripheral | General disorders | Glimepiride 2 mg and Metformin 850 mg BID | 4 | 149 | |
| serious | Abdominal adhesions | Gastrointestinal disorders | Pioglitazone 15 mg and Metformin 850 mg BID | 0 | 153 | |
| serious | Abdominal adhesions | Gastrointestinal disorders | Glimepiride 2 mg and Metformin 850 mg BID | 1 | 149 | |
| serious | Benign breast neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Pioglitazone 15 mg and Metformin 850 mg BID | 1 | 153 | |
| serious | Benign breast neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Glimepiride 2 mg and Metformin 850 mg BID | 0 | 149 | |
| serious | Cardiac failure | Cardiac disorders | Pioglitazone 15 mg and Metformin 850 mg BID | 2 | 153 | |
| serious | Cardiac failure | Cardiac disorders | Glimepiride 2 mg and Metformin 850 mg BID | 0 | 149 | |
| serious | Cardiomegaly | Cardiac disorders | Pioglitazone 15 mg and Metformin 850 mg BID | 1 | 153 | |
| serious | Cardiomegaly | Cardiac disorders | Glimepiride 2 mg and Metformin 850 mg BID | 0 | 149 | |
| serious | Carotid artery stenosis | Nervous system disorders | Pioglitazone 15 mg and Metformin 850 mg BID | 0 | 153 | |
| serious | Carotid artery stenosis | Nervous system disorders | Glimepiride 2 mg and Metformin 850 mg BID | 1 | 149 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00770653/events